vs
拜玛林制药（BMRN）与REPUBLIC AIRWAYS HOLDINGS INC.（RJET）财务数据对比。点击上方公司名可切换其他公司
REPUBLIC AIRWAYS HOLDINGS INC.的季度营收约是拜玛林制药的1.2倍（$1.1B vs $874.6M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 3.9%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
共和航空控股是一家总部位于美国印第安纳州印第安纳波利斯的航空控股企业，旗下拥有梅萨航空与共和航空两家支线航空公司。两家公司合计运营的巴航工业E170与E175客机规模为全球第一，公司多数股权由与其签订合作协议的美国航空、达美航空、联合航空这几家干线航司持有。
BMRN vs RJET — 直观对比
营收规模更大
RJET
是对方的1.2倍
$874.6M
两年增速更快
BMRN
近两年复合增速
3.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $1.1B |
| 净利润 | $-46.6M | — |
| 毛利率 | 68.5% | — |
| 营业利润率 | -5.1% | 22.0% |
| 净利率 | -5.3% | — |
| 营收同比 | 17.0% | — |
| 净利润同比 | -137.3% | — |
| 每股收益（稀释后） | $-0.22 | $3.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRJET
| Q4 25 | $874.6M | $1.1B | ||
| Q3 25 | $776.1M | $90.7M | ||
| Q2 25 | $825.4M | $92.8M | ||
| Q1 25 | $745.1M | $94.7M | ||
| Q4 24 | $747.3M | $808.3M | ||
| Q3 24 | $745.7M | — | ||
| Q2 24 | $712.0M | $110.8M | ||
| Q1 24 | $648.8M | $131.6M |
净利润BMRNRJET
| Q4 25 | $-46.6M | — | ||
| Q3 25 | $-30.7M | $-14.1M | ||
| Q2 25 | $240.5M | $20.9M | ||
| Q1 25 | $185.7M | $-58.6M | ||
| Q4 24 | $124.9M | $97.8M | ||
| Q3 24 | $106.1M | — | ||
| Q2 24 | $107.2M | $-19.9M | ||
| Q1 24 | $88.7M | $11.7M |
毛利率BMRNRJET
| Q4 25 | 68.5% | — | ||
| Q3 25 | 82.0% | — | ||
| Q2 25 | 81.8% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 74.7% | — | ||
| Q2 24 | 81.7% | — | ||
| Q1 24 | 80.7% | — |
营业利润率BMRNRJET
| Q4 25 | -5.1% | 22.0% | ||
| Q3 25 | -6.0% | -10.1% | ||
| Q2 25 | 33.5% | -0.2% | ||
| Q1 25 | 30.0% | -60.4% | ||
| Q4 24 | 21.6% | 18.7% | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 16.9% | -8.1% | ||
| Q1 24 | 13.6% | 8.8% |
净利率BMRNRJET
| Q4 25 | -5.3% | — | ||
| Q3 25 | -4.0% | -15.6% | ||
| Q2 25 | 29.1% | 22.5% | ||
| Q1 25 | 24.9% | -61.9% | ||
| Q4 24 | 16.7% | 12.1% | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 15.1% | -18.0% | ||
| Q1 24 | 13.7% | 8.9% |
每股收益（稀释后）BMRNRJET
| Q4 25 | $-0.22 | $3.13 | ||
| Q3 25 | $-0.16 | $-0.34 | ||
| Q2 25 | $1.23 | $0.50 | ||
| Q1 25 | $0.95 | $-1.42 | ||
| Q4 24 | $0.65 | $2.42 | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $0.55 | $-0.48 | ||
| Q1 24 | $0.46 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $296.5M |
| 总债务越低越好 | — | $882.9M |
| 股东权益账面价值 | $6.1B | $1.3B |
| 总资产 | $7.6B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资BMRNRJET
| Q4 25 | $1.3B | $296.5M | ||
| Q3 25 | $1.3B | $38.7M | ||
| Q2 25 | $1.2B | $42.5M | ||
| Q1 25 | $1.0B | $54.1M | ||
| Q4 24 | $942.8M | $302.0M | ||
| Q3 24 | $675.4M | — | ||
| Q2 24 | $972.1M | $16.3M | ||
| Q1 24 | $747.0M | $18.5M |
总债务BMRNRJET
| Q4 25 | — | $882.9M | ||
| Q3 25 | — | $27.0M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | — | $31.7M | ||
| Q4 24 | — | $752.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $287.7M | ||
| Q1 24 | — | $299.0M |
股东权益BMRNRJET
| Q4 25 | $6.1B | $1.3B | ||
| Q3 25 | $6.1B | $-52.6M | ||
| Q2 25 | $6.0B | $-38.7M | ||
| Q1 25 | $5.8B | $-59.8M | ||
| Q4 24 | $5.7B | $1.1B | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.3B | $134.9M | ||
| Q1 24 | $5.1B | $154.7M |
总资产BMRNRJET
| Q4 25 | $7.6B | $3.3B | ||
| Q3 25 | $7.6B | $158.9M | ||
| Q2 25 | $7.5B | $178.6M | ||
| Q1 25 | $7.1B | $215.0M | ||
| Q4 24 | $7.0B | $2.8B | ||
| Q3 24 | $6.9B | — | ||
| Q2 24 | $7.1B | $664.4M | ||
| Q1 24 | $6.9B | $706.3M |
负债/权益比BMRNRJET
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.13× | ||
| Q1 24 | — | 1.93× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | — |
| 自由现金流经营现金流 - 资本支出 | $58.9M | — |
| 自由现金流率自由现金流/营收 | 6.7% | — |
| 资本支出强度资本支出/营收 | 4.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | — |
8季度趋势，按日历期对齐
经营现金流BMRNRJET
| Q4 25 | $99.6M | — | ||
| Q3 25 | $368.7M | — | ||
| Q2 25 | $185.3M | $-9.4M | ||
| Q1 25 | $174.4M | — | ||
| Q4 24 | $185.6M | $184.0M | ||
| Q3 24 | $221.5M | — | ||
| Q2 24 | $118.8M | $11.2M | ||
| Q1 24 | $47.0M | — |
自由现金流BMRNRJET
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | $-10.5M | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | $-42.7M | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | $7.5M | ||
| Q1 24 | $20.9M | — |
自由现金流率BMRNRJET
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | -11.3% | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | -5.3% | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | 6.8% | ||
| Q1 24 | 3.2% | — |
资本支出强度BMRNRJET
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | 1.2% | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | 28.0% | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | 3.4% | ||
| Q1 24 | 4.0% | — |
现金转化率BMRNRJET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | -0.45× | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | 1.88× | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RJET
| United Airlines | $517.5M | 48% |
| Delta Air Lines | $409.7M | 38% |
| Other | $49.9M | 5% |
| Republic Airways Holdings Inc. | $42.2M | 4% |
| Other Airlines | $25.7M | 2% |
| LIFT Academy | $23.2M | 2% |
